Remove Access Remove Clinical Trials Remove Data Remove Topical
article thumbnail

CDC Seeks Public Comments Regarding Chronic Pain Management

NORML

The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management.

article thumbnail

Data Analysis Yields Insights Into Medical Cannabis Use, Efficacy

Cannabis Law Report

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.

Data 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cannabis 3.0 Accelerates Access to Consumer and Medical Research

Cannabis Law Report

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

article thumbnail

More than half of prescriptions for medicinal cannabis in Australia given in Queensland, study says

Cannabis Law Report

Data obtained through a freedom of information request to drugs regulator the Therapeutic Goods Administration (TGA) revealed the age of those prescribed the drugs, the reason for prescribing, and the state or territory where the prescription was made. We are aware of clinical trials in that space, but not strong evidence.”.

article thumbnail

Vice Article: Australians Can Get a Medicinal Cannabis Prescription for Pretty Much Anything

Cannabis Law Report

First academic study of national medicinal cannabis data. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. The authors note, however, that the data doesn’t include patient outcomes. Here’s the Uni of Sydney press release. 11 May 2022.

article thumbnail

‘The most meaningful cannabis reform in decades’: Experts weigh in on new DEA rules

The Cannigma

‘Junk’ cannabis ‘ill-suited for clinical trials’. The cannabis grown at the University of Mississippi “is junk, ill-suited for clinical trials, and genetically closer to hemp than the marijuana available from dispensaries and used by Americans nationwide,” according to the lawsuit.

DEA 133
article thumbnail

CBD Science Update

Project CBD

Over 200 scientists from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpiblished data. Results highlight the need for expanded patient access to CBD products.”.

CBD 218